Tscan Therapeutics (NASDAQ:TCRX) Shares Down 6.9%

Tscan Therapeutics, Inc. (NASDAQ:TCRX)’s stock price fell 6.9% during trading on Monday . The company traded as low as $7.57 and last traded at $7.64. 58,724 shares traded hands during trading, a decline of 28% from the average session volume of 81,446 shares. The stock had previously closed at $8.21.

A number of research firms recently commented on TCRX. Jefferies Financial Group began coverage on shares of Tscan Therapeutics in a research report on Tuesday, August 10th. They set a “buy” rating and a $21.00 price target on the stock. Morgan Stanley assumed coverage on shares of Tscan Therapeutics in a report on Tuesday, August 10th. They issued an “overweight” rating and a $22.00 target price on the stock. Cowen assumed coverage on shares of Tscan Therapeutics in a report on Friday, August 13th. They issued an “outperform” rating on the stock. Finally, Barclays assumed coverage on shares of Tscan Therapeutics in a report on Tuesday, August 10th. They issued an “overweight” rating and a $22.00 target price on the stock.

The company’s 50 day moving average is $9.79.

Tscan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Wednesday, August 18th. The company reported ($7.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($7.04). The firm had revenue of $2.85 million for the quarter. On average, research analysts forecast that Tscan Therapeutics, Inc. will post -7.72 earnings per share for the current fiscal year.

Tscan Therapeutics Company Profile (NASDAQ:TCRX)

TScan Therapeutics Inc is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company’s lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc is based in WALTHAM, Mass.

See Also: Market Timing

Receive News & Ratings for Tscan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tscan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.